Successful Desensitization and Therapeutic Use of Infliximab in Adult and Pediatric Crohn's Disease Patients With Prior Anaphylactic Reaction
Open Access
- 1 February 2001
- journal article
- case report
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 7 (1) , 34-37
Abstract
Summary. Infusion of the antitumor necrosis factor-α chimeric monoclonal antibody infliximab is highly effective in the treatment of refractory and fistulizingKeywords
This publication has 7 references indexed in Scilit:
- Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's diseaseGastroenterology, 1999
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- DRUG CHALLENGE AND DESENSITIZATION PROTOCOLSImmunology and Allergy Clinics of North America, 1998
- PrefaceJournal of Allergy and Clinical Immunology, 1998
- Biologic agents: data in adults and children.Inflammatory Bowel Diseases, 1998
- Allergic Reactions to Drugs and Biologic AgentsJAMA, 1997
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997